Navigation Links
Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
Date:10/24/2011

SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, for the diabetes, cancer, dermatology and drug delivery markets, today announced its upcoming poster presentation for PEGPH20 at the 2011 EORTC-NCI-ASCO Annual Meeting, taking place October 27-29 in Brussels, Belgium. Halozyme's PEGPH20 is a PEGylated form of rHuPH20 that is being evaluated in an ongoing Phase 2 clinical trial in patients with stage IV previously untreated pancreatic cancer. The poster and abstract will also be published in the "European Journal of Cancer" proceeding book of the conference. Details of the poster session and discussion are as follows:

Thursday, October 27, 2011

12:00 – 8:30 p.m. CET: Targeting hyaluronan in tumor stroma. Interim translational and biomarker evaluations of pegylated hyaluronidase (PEGPH20) in patients with advanced solid tumors   (Discussion from 6:00 – 8:30 p.m. CET)

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Hercept
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oregon , October 22, 2014 ... "Global Disposable Gloves Market (Product type, Form, End user, ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... global disposable gloves market. Based on key trends tracked, ... be valued at $7.9 billion by 2020, registering a ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... /PRNewswire/ -- A new study suggests,strong variation in ... U.S. Anaphylaxis is a severe allergic,reaction that can ... differences in EpiPen prescribing, a marker of,anaphylaxis risk, ... low levels of vitamin D,from lack of sunshine, ...
... Journal of the,American Society of Clinical Oncology has ... by Dr. Siu-Fun Wong, and her,colleagues, which concluded ... reduction in the pain and,itching of a rash ... as EGFR inhibitors. This ongoing supportive care trial ...
Cached Medicine Technology:Large Geographic Differences in EpiPen Prescriptions in the U.S.,From the Journal of Allergy and Clinical Immunology 2Clinical Study Shows Regenecare Relieves Pain and Itching of Skin,Rashes Caused by Widely Used Cancer Drugs 2
(Date:10/25/2014)... New York, New York (PRWEB) October 25, 2014 ... lawsuits ( http://www.thexareltolawsuit.com/ ) will be addressed in December, ... convenes its next hearing session. According to a Hearing ... Oral Arguments on the matter will be heard on ... Session will begin at 9:30 a.m. (In Re: Xarelto ...
(Date:10/25/2014)... Madison, WI (PRWEB) October 25, 2014 ... of tax-advantaged medical and other benefits account management ... designed to help employers save on taxes, reduce ... new Suites provide tax savings and the efficient ... can pick the Suite that best meets their ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The ... ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston Scientific ... U.S. District Court, Southern District of West Virginia ... on Punitive Damages in a group of cases ... ruling issued on October 21st, U.S. District Judge ...
(Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
(Date:10/25/2014)... 2014 (HealthDay News) -- October,s shorter, darker days can ... disorder, according to an expert. People affected ... overly tired, lack motivation and even have trouble getting ... to suicide, said Dr. Angelos Halaris, a professor in ... University Chicago Stitch School of Medicine. "Seasonal affective ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... Successful, OWINGS MILLS, Md., Oct. 4 Medifast, ... the current business outlook, the,Company is updating full year ... expects to report revenue of $81 to $83 million ... Previously, the Company,expected to report revenue of $85 to ...
... just part of what is ... local nonprofit for teens., WILSONVILLE, Ore., Oct. 4 On Tuesday, ... in furniture,arcade games and supplies. These and other items, unused for at ... to the,Sexual Minority Youth Resource Center (SMYRC). Volunteer crews will move ...
... - A new American Heart,Association survey (1) shows consumer awareness of the ... high. But consumers still need,some key information to improve how they eat., ... Fats Are The survey shows that:, --While 92 percent of ... jump from 84 percent in 2006 - only 21 percent can name ...
... revealing how toxic chemicals disrupt gene activity and other ... -- and why some individuals are particularly vulnerable. For ... more likely to experience side effects from certain medications, ... , How can this type of research -- known ...
... 22 new centers now added, first participants set to join ... -- The largest study ever of the impact of environment ... directed from 22 new centers across the United States, organizers ... first participants enrolled in the National Children,s Study should be ...
... president and CCO of,KickSkirt, Inc., will lead a ... the health of their children while also improving ... The Marketing-To-Moms Conference,October 23-24, 2007, Chicago Cultural Center. ... and medical director of Peak Wellness and star ...
Cached Medicine News:Health News:Medifast Announces Updated Full Year 2007 Guidance 2Health News:Medifast Announces Updated Full Year 2007 Guidance 3Health News:Medifast Announces Updated Full Year 2007 Guidance 4Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 2Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 3Health News:Americans' Knowledge of Fats Growing But Still Insufficient 2Health News:Americans' Knowledge of Fats Growing But Still Insufficient 3Health News:Largest Study of U.S. Children Readies for Launch 2Health News:Brands Tackle the Childhood Obesity Issue During M2Moms(TM) - The Marketing-To-Moms Conference 2
... lightweight self-adhesive insulin pod that you fill with ... up to three days and then replace. The ... your body through a small flexible tube (called ... into its wireless companion, the Personal Diabetes Manager. ...
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
The IR 1000 Insulin Infusion Pump from Animas offers unprecedented safety features, performance, and convenience....
... premium product for acne, XtremeClear, powered ... on a scalable multi-application platform. A ... acne, XtremeClear works fast, providing noticeable ... treatments. Uncompromising safety in each of ...
Medicine Products: